Superworth

CRISPR Therapeutics profit margin CRSP

Gross, operating and net profit as a share of revenue over the last twelve months, from 2019.

Net margin, 12 months
n/m
not a meaningful number
Peer median
26.3%

CRISPR Therapeutics' net margin works out at −3369% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023−41.4%−60.0%
FY2022n/an/a
FY202141.3%40.8%
FY2020n/an/a
FY201923.1%16.1%
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24−79.9%n/an/a
Q4 FY23−41.4%n/a−60.0%
Q3 FY23n/an/an/a

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

CompanyProfit margin
CRSPCRISPR Therapeuticsn/m
KRYSKrystal Biotech54.8%
ADMAAdma Biologics33.0%
RGENRepligen5.3%
VCELVericel7.9%
TECHBIO-TECHNE15.0%
HALOHalozyme Therapeutics24.9%
NBIXNeurocrine Biosciences20.9%
EXELExelixis35.3%
INCYIncyte27.7%
UTHRUnited Therapeutics41.6%
Peer median26.3%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.